Post by stcks on Dec 3, 2017 18:39:34 GMT
Loxo Oncology Is A Buy Ahead Of Data Update
Dec. 3, 2017 8:15 AM • LOXO
www.seekingalpha.com/article/4129245
Summary
* Loxo Oncology is a buy ahead of clinical data.
* LOXO's lead candidate, Larotrectinib, will shine and head towards NDA submission.
* The company's pipeline looks promising.
Larotrectinib (LOXO-101) is a collaboration with Array BioPharma
Loxo Oncology, Inc. (NASDAQ:LOXO) has shown excellent results from its drug candidate Larotrectinib, and now is an excellent entry point ahead of new data. The company will update on December 4-5, 2017, on previously impressive top-line data from the pediatric trial (SCOUT). Previous data on this was presented at the American Society of Clinical Oncology (ASCO) meeting in June.
Larotrectinib is an oral, selective inhibitor of the tropomyosin receptor kinase (TRK). Fusions involving TRK drive a number of various tumor types, such as breast cancer, colorectal cancer, head and neck cancer, melanoma, and thyroid cancer.
TRK consists of three cell receptor proteins which are encoded by NTRK1, NTRK2, and NTRK3 genes. If TRK genes fuse incorrectly, it can lead to cancer and drive tumor progression. The improper gene fusions will remain active without any activation signal, leading to genetically-linked tumors harboring TRK fusions. Larotrectinib is a cancer therapeutic that targets TRK genetic alterations.
See the slides and rest of the article via the following link. www.seekingalpha.com/article/4129245
Dec. 3, 2017 8:15 AM • LOXO
www.seekingalpha.com/article/4129245
Summary
* Loxo Oncology is a buy ahead of clinical data.
* LOXO's lead candidate, Larotrectinib, will shine and head towards NDA submission.
* The company's pipeline looks promising.
Larotrectinib (LOXO-101) is a collaboration with Array BioPharma
Loxo Oncology, Inc. (NASDAQ:LOXO) has shown excellent results from its drug candidate Larotrectinib, and now is an excellent entry point ahead of new data. The company will update on December 4-5, 2017, on previously impressive top-line data from the pediatric trial (SCOUT). Previous data on this was presented at the American Society of Clinical Oncology (ASCO) meeting in June.
Larotrectinib is an oral, selective inhibitor of the tropomyosin receptor kinase (TRK). Fusions involving TRK drive a number of various tumor types, such as breast cancer, colorectal cancer, head and neck cancer, melanoma, and thyroid cancer.
TRK consists of three cell receptor proteins which are encoded by NTRK1, NTRK2, and NTRK3 genes. If TRK genes fuse incorrectly, it can lead to cancer and drive tumor progression. The improper gene fusions will remain active without any activation signal, leading to genetically-linked tumors harboring TRK fusions. Larotrectinib is a cancer therapeutic that targets TRK genetic alterations.
See the slides and rest of the article via the following link. www.seekingalpha.com/article/4129245
